{
  "success": true,
  "pagesUsed": [
    2,
    3,
    4,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    19,
    20,
    21,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To evaluate the efficacy of faricimab 6 mg IVT Q4W compared with aflibercept 2 mg IVT Q4W",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Efficacy Objective Part 1",
        "text": "To evaluate the efficacy of faricimab compared with aflibercept through Week 24",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2",
          "ep_3",
          "ep_4",
          "ep_5",
          "ep_6",
          "ep_7",
          "ep_8",
          "ep_9",
          "ep_10"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Efficacy Objective Part 2",
        "text": "To evaluate the efficacy of faricimab administered according to the PTI dosing regimen from Week 24 through Week 72",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_11",
          "ep_12",
          "ep_13",
          "ep_14",
          "ep_15",
          "ep_16",
          "ep_17",
          "ep_18",
          "ep_19",
          "ep_20",
          "ep_21",
          "ep_22",
          "ep_23"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Exploratory Efficacy Objective",
        "text": "To evaluate the efficacy of faricimab on the basis of retinal ischemia and vascular leakage",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_24",
          "ep_25",
          "ep_26",
          "ep_27"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "Change from baseline in BCVA at Week 24",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Secondary Efficacy Endpoint 1",
        "text": "Change from baseline in BCVA at specified timepoints through Week 24",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary Efficacy Endpoint 2",
        "text": "Proportion of patients gaining >=15 letters in BCVA from baseline at Week 24",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Secondary Efficacy Endpoint 3",
        "text": "Proportion of patients gaining >=15, >=10, >=5, or >0 letters in BCVA from baseline at specified timepoints through Week 24",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Secondary Efficacy Endpoint 4",
        "text": "Proportion of patients avoiding a loss of >=15, >=10, >=5, or >0 letters in BCVA from baseline at specified timepoints through Week 24",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Secondary Efficacy Endpoint 5",
        "text": "Proportion of patients achieving >=84 letters (20/20 Snellen equivalent) in BCVA at specified timepoints through Week 24",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Secondary Efficacy Endpoint 6",
        "text": "Proportion of patients with BCVA Snellen equivalent of 20/40 or better at specified timepoints through Week 24",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Secondary Efficacy Endpoint 7",
        "text": "Proportion of patients with BCVA Snellen equivalent of 20/200 or worse at specified timepoints through Week 24",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_9",
        "name": "Secondary Efficacy Endpoint 8",
        "text": "Change from baseline in central subfield thickness (CST) at specified timepoints through Week 24",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_10",
        "name": "Secondary Efficacy Endpoint 9",
        "text": "Change from baseline in National Eye Institute 25-Item Visual Functioning Questionnaire (NEI VFQ-25) composite score at specified timepoints through Week 24",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_11",
        "name": "Secondary Efficacy Endpoint 10",
        "text": "Change from baseline in BCVA at specified timepoints from Week 24 through Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_12",
        "name": "Secondary Efficacy Endpoint 11",
        "text": "Proportion of patients gaining >=15 letters in BCVA from baseline at Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_13",
        "name": "Secondary Efficacy Endpoint 12",
        "text": "Proportion of patients gaining >=15, >=10, >=5, or >0 letters in BCVA from baseline at specified timepoints from Week 24 through Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_14",
        "name": "Secondary Efficacy Endpoint 13",
        "text": "Proportion of patients avoiding a loss of >=15, >=10, >=5, or >0 letters in BCVA from baseline at specified timepoints from Week 24 through Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_15",
        "name": "Secondary Efficacy Endpoint 14",
        "text": "Proportion of patients achieving >=84 letters (20/20 Snellen equivalent) in BCVA at specified timepoints from Week 24 through Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_16",
        "name": "Secondary Efficacy Endpoint 15",
        "text": "Proportion of patients with BCVA Snellen equivalent of 20/40 or better at specified timepoints from Week 24 through Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_17",
        "name": "Secondary Efficacy Endpoint 16",
        "text": "Proportion of patients with BCVA Snellen equivalent of 20/200 or worse at specified timepoints from Week 24 through Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_18",
        "name": "Secondary Efficacy Endpoint 17",
        "text": "Change from Week 24 in BCVA at specified timepoints through Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_19",
        "name": "Secondary Efficacy Endpoint 18",
        "text": "Proportion of patients avoiding a loss of >=15, >=10, >=5, or >0 letters in BCVA from Week 24 through Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_20",
        "name": "Secondary Efficacy Endpoint 19",
        "text": "Proportion of patients on a Q4W, every 8 weeks (Q8W), every 12 weeks (Q12W), or Q16W treatment interval at Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_21",
        "name": "Secondary Efficacy Endpoint 20",
        "text": "Number of study drug injections received from Week 24 through Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_22",
        "name": "Secondary Efficacy Endpoint 21",
        "text": "Change from baseline in CST at specified timepoints from Week 24 through Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_23",
        "name": "Secondary Efficacy Endpoint 22",
        "text": "Change from baseline in NEI VFQ-25 composite score at specified timepoints from Week 24 through Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_24",
        "name": "Exploratory Efficacy Endpoint 1",
        "text": "Proportion of patients with absence of retinal ischemia on fundus fluorescein angiography (FFA) and on optical coherence tomography angiography (OCT-A) (optional) over time (at specified timepoints)",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_25",
        "name": "Exploratory Efficacy Endpoint 2",
        "text": "Change from baseline in area of retinal ischemia on FFA and on OCT-A (optional) over time",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_26",
        "name": "Exploratory Efficacy Endpoint 3",
        "text": "Proportion of patients with vascular leakage on FFA and on OCT-A (optional) over time",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_27",
        "name": "Exploratory Efficacy Endpoint 4",
        "text": "Change from baseline in area of vascular leakage on FFA, and on OCT-A (optional) over time",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand",
        "populationSummary": "Adult patients with macular edema secondary to branch retinal vein occlusion (ITT population) Summary measure: Difference in least squares means.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Subject discontinues study drug prior to Week 24",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Use of rescue medication",
            "text": "Use of prohibited ocular treatments or rescue therapy",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_3",
            "name": "Death",
            "text": "Death of the patient prior to Week 24",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Faricimab 6 mg IVT Q4W vs Aflibercept 2 mg IVT Q4W",
        "analysisPopulation": "Adult patients with macular edema secondary to branch retinal vein occlusion (ITT population)",
        "variableOfInterest": "Change from baseline in BCVA at Week 24",
        "summaryMeasure": "Difference in least squares means"
      },
      {
        "id": "est_2",
        "name": "Secondary Efficacy Estimand - Gain of 15 letters",
        "populationSummary": "Adult patients with macular edema secondary to branch retinal vein occlusion (ITT population) Summary measure: Difference in proportions.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Subject discontinues study drug prior to Week 24",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Faricimab 6 mg IVT Q4W vs Aflibercept 2 mg IVT Q4W",
        "analysisPopulation": "Adult patients with macular edema secondary to branch retinal vein occlusion (ITT population)",
        "variableOfInterest": "Proportion of patients gaining >=15 letters in BCVA from baseline at Week 24",
        "summaryMeasure": "Difference in proportions"
      }
    ],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 2,
      "exploratoryObjectives": 1,
      "totalEndpoints": 27,
      "totalEstimands": 2
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To evaluate the efficacy of faricimab 6 mg IVT Q4W compared with aflibercept 2 mg IVT Q4W",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Efficacy Objective Part 1",
        "text": "To evaluate the efficacy of faricimab compared with aflibercept through Week 24",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2",
          "ep_3",
          "ep_4",
          "ep_5",
          "ep_6",
          "ep_7",
          "ep_8",
          "ep_9",
          "ep_10"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Efficacy Objective Part 2",
        "text": "To evaluate the efficacy of faricimab administered according to the PTI dosing regimen from Week 24 through Week 72",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_11",
          "ep_12",
          "ep_13",
          "ep_14",
          "ep_15",
          "ep_16",
          "ep_17",
          "ep_18",
          "ep_19",
          "ep_20",
          "ep_21",
          "ep_22",
          "ep_23"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Exploratory Efficacy Objective",
        "text": "To evaluate the efficacy of faricimab on the basis of retinal ischemia and vascular leakage",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_24",
          "ep_25",
          "ep_26",
          "ep_27"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "Change from baseline in BCVA at Week 24",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Secondary Efficacy Endpoint 1",
        "text": "Change from baseline in BCVA at specified timepoints through Week 24",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary Efficacy Endpoint 2",
        "text": "Proportion of patients gaining >=15 letters in BCVA from baseline at Week 24",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Secondary Efficacy Endpoint 3",
        "text": "Proportion of patients gaining >=15, >=10, >=5, or >0 letters in BCVA from baseline at specified timepoints through Week 24",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Secondary Efficacy Endpoint 4",
        "text": "Proportion of patients avoiding a loss of >=15, >=10, >=5, or >0 letters in BCVA from baseline at specified timepoints through Week 24",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Secondary Efficacy Endpoint 5",
        "text": "Proportion of patients achieving >=84 letters (20/20 Snellen equivalent) in BCVA at specified timepoints through Week 24",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Secondary Efficacy Endpoint 6",
        "text": "Proportion of patients with BCVA Snellen equivalent of 20/40 or better at specified timepoints through Week 24",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Secondary Efficacy Endpoint 7",
        "text": "Proportion of patients with BCVA Snellen equivalent of 20/200 or worse at specified timepoints through Week 24",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_9",
        "name": "Secondary Efficacy Endpoint 8",
        "text": "Change from baseline in central subfield thickness (CST) at specified timepoints through Week 24",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_10",
        "name": "Secondary Efficacy Endpoint 9",
        "text": "Change from baseline in National Eye Institute 25-Item Visual Functioning Questionnaire (NEI VFQ-25) composite score at specified timepoints through Week 24",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_11",
        "name": "Secondary Efficacy Endpoint 10",
        "text": "Change from baseline in BCVA at specified timepoints from Week 24 through Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_12",
        "name": "Secondary Efficacy Endpoint 11",
        "text": "Proportion of patients gaining >=15 letters in BCVA from baseline at Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_13",
        "name": "Secondary Efficacy Endpoint 12",
        "text": "Proportion of patients gaining >=15, >=10, >=5, or >0 letters in BCVA from baseline at specified timepoints from Week 24 through Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_14",
        "name": "Secondary Efficacy Endpoint 13",
        "text": "Proportion of patients avoiding a loss of >=15, >=10, >=5, or >0 letters in BCVA from baseline at specified timepoints from Week 24 through Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_15",
        "name": "Secondary Efficacy Endpoint 14",
        "text": "Proportion of patients achieving >=84 letters (20/20 Snellen equivalent) in BCVA at specified timepoints from Week 24 through Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_16",
        "name": "Secondary Efficacy Endpoint 15",
        "text": "Proportion of patients with BCVA Snellen equivalent of 20/40 or better at specified timepoints from Week 24 through Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_17",
        "name": "Secondary Efficacy Endpoint 16",
        "text": "Proportion of patients with BCVA Snellen equivalent of 20/200 or worse at specified timepoints from Week 24 through Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_18",
        "name": "Secondary Efficacy Endpoint 17",
        "text": "Change from Week 24 in BCVA at specified timepoints through Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_19",
        "name": "Secondary Efficacy Endpoint 18",
        "text": "Proportion of patients avoiding a loss of >=15, >=10, >=5, or >0 letters in BCVA from Week 24 through Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_20",
        "name": "Secondary Efficacy Endpoint 19",
        "text": "Proportion of patients on a Q4W, every 8 weeks (Q8W), every 12 weeks (Q12W), or Q16W treatment interval at Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_21",
        "name": "Secondary Efficacy Endpoint 20",
        "text": "Number of study drug injections received from Week 24 through Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_22",
        "name": "Secondary Efficacy Endpoint 21",
        "text": "Change from baseline in CST at specified timepoints from Week 24 through Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_23",
        "name": "Secondary Efficacy Endpoint 22",
        "text": "Change from baseline in NEI VFQ-25 composite score at specified timepoints from Week 24 through Week 72",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_24",
        "name": "Exploratory Efficacy Endpoint 1",
        "text": "Proportion of patients with absence of retinal ischemia on fundus fluorescein angiography (FFA) and on optical coherence tomography angiography (OCT-A) (optional) over time (at specified timepoints)",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_25",
        "name": "Exploratory Efficacy Endpoint 2",
        "text": "Change from baseline in area of retinal ischemia on FFA and on OCT-A (optional) over time",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_26",
        "name": "Exploratory Efficacy Endpoint 3",
        "text": "Proportion of patients with vascular leakage on FFA and on OCT-A (optional) over time",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_27",
        "name": "Exploratory Efficacy Endpoint 4",
        "text": "Change from baseline in area of vascular leakage on FFA, and on OCT-A (optional) over time",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand",
        "populationSummary": "Adult patients with macular edema secondary to branch retinal vein occlusion (ITT population) Summary measure: Difference in least squares means.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Subject discontinues study drug prior to Week 24",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Use of rescue medication",
            "text": "Use of prohibited ocular treatments or rescue therapy",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_3",
            "name": "Death",
            "text": "Death of the patient prior to Week 24",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Faricimab 6 mg IVT Q4W vs Aflibercept 2 mg IVT Q4W",
        "analysisPopulation": "Adult patients with macular edema secondary to branch retinal vein occlusion (ITT population)",
        "variableOfInterest": "Change from baseline in BCVA at Week 24",
        "summaryMeasure": "Difference in least squares means"
      },
      {
        "id": "est_2",
        "name": "Secondary Efficacy Estimand - Gain of 15 letters",
        "populationSummary": "Adult patients with macular edema secondary to branch retinal vein occlusion (ITT population) Summary measure: Difference in proportions.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Subject discontinues study drug prior to Week 24",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Faricimab 6 mg IVT Q4W vs Aflibercept 2 mg IVT Q4W",
        "analysisPopulation": "Adult patients with macular edema secondary to branch retinal vein occlusion (ITT population)",
        "variableOfInterest": "Proportion of patients gaining >=15 letters in BCVA from baseline at Week 24",
        "summaryMeasure": "Difference in proportions"
      }
    ]
  }
}